KRYS
Price
$174.44
Change
-$5.85 (-3.24%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
5.03B
40 days until earnings call
REGN
Price
$617.00
Change
-$17.23 (-2.72%)
Updated
Apr 1 closing price
Capitalization
67.45B
27 days until earnings call
Ad is loading...

KRYS vs REGN

Header iconKRYS vs REGN Comparison
Open Charts KRYS vs REGNBanner chart's image
Krystal Biotech
Price$174.44
Change-$5.85 (-3.24%)
Volume$4.82K
Capitalization5.03B
Regeneron Pharmaceuticals
Price$617.00
Change-$17.23 (-2.72%)
Volume$1.06M
Capitalization67.45B
KRYS vs REGN Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. REGN commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and REGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (KRYS: $180.30 vs. REGN: $634.23)
Brand notoriety: KRYS: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 124% vs. REGN: 113%
Market capitalization -- KRYS: $5.03B vs. REGN: $67.45B
KRYS [@Biotechnology] is valued at $5.03B. REGN’s [@Biotechnology] market capitalization is $67.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 2 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).

  • KRYS’s TA Score: 2 bullish, 6 bearish.
  • REGN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, REGN is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -7.27% price change this week, while REGN (@Biotechnology) price change was -4.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

KRYS is expected to report earnings on May 12, 2025.

REGN is expected to report earnings on Apr 29, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($67.5B) has a higher market cap than KRYS($5.03B). KRYS has higher P/E ratio than REGN: KRYS (58.19) vs REGN (16.09). KRYS YTD gains are higher at: 15.090 vs. REGN (-10.850). REGN has higher annual earnings (EBITDA): 5.32B vs. KRYS (110M). REGN has more cash in the bank: 9.01B vs. KRYS (598M). KRYS has less debt than REGN: KRYS (7.26M) vs REGN (2.7B). REGN has higher revenues than KRYS: REGN (14.2B) vs KRYS (291M).
KRYSREGNKRYS / REGN
Capitalization5.03B67.5B7%
EBITDA110M5.32B2%
Gain YTD15.090-10.850-139%
P/E Ratio58.1916.09362%
Revenue291M14.2B2%
Total Cash598M9.01B7%
Total Debt7.26M2.7B0%
FUNDAMENTALS RATINGS
KRYS vs REGN: Fundamental Ratings
KRYS
REGN
OUTLOOK RATING
1..100
7863
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
1873
SMR RATING
1..100
6854
PRICE GROWTH RATING
1..100
4564
P/E GROWTH RATING
1..100
10089
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for KRYS (79) in the Pharmaceuticals Major industry. This means that REGN’s stock grew significantly faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (73) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is in the same range as KRYS (68) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as REGN (64) in the Biotechnology industry. This means that KRYS’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (89) in the Biotechnology industry is in the same range as KRYS (100) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSREGN
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 14 days ago
76%
Bullish Trend 23 days ago
61%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 12 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
45%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSEX64.100.62
+0.98%
Middlesex Water Company
PINE16.720.11
+0.66%
Alpine Income Property Trust
WRB71.16-0.11
-0.15%
WR Berkley Corp
CNX31.48-0.15
-0.47%
CNX Resources Corp
PAVM0.72-0.03
-3.81%
PAVmed

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-1.97%
IDYA - KRYS
50%
Loosely correlated
-3.93%
ACLX - KRYS
48%
Loosely correlated
-3.47%
CRNX - KRYS
47%
Loosely correlated
-3.43%
ZLDPF - KRYS
45%
Loosely correlated
-0.66%
CGON - KRYS
45%
Loosely correlated
-7.31%
More